Search hospitals > Tennessee > Nashville
Vanderbilt-Ingram Cancer Center
Claim this profileNashville, Tennessee 37212
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Tumors
Conducts research for Lymphoma
Conducts research for Breast Cancer
1090 reported clinical trials
68 medical researchers
Summary
Vanderbilt-Ingram Cancer Center is a medical facility located in Nashville, Tennessee. This center is recognized for care of Cancer, Leukemia, Tumors, Lymphoma, Breast Cancer and other specialties. Vanderbilt-Ingram Cancer Center is involved with conducting 1,090 clinical trials across 833 conditions. There are 68 research doctors associated with this hospital, such as Scott Borinstein, M.D., Michael Gibson, Elizabeth J. Davis, and David D. Chism.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Leukemia
Global LeaderPhiladelphia chromosome positive
Stage II
Stage I
Top PIs
Scott Borinstein, M.D.Vanderbilt University/Ingram Cancer Center7 years of reported clinical research
Expert in Rhabdomyosarcoma
Expert in Osteosarcoma
30 reported clinical trials
52 drugs studied
Michael GibsonVanderbilt University/Ingram Cancer Center4 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
17 reported clinical trials
36 drugs studied
Elizabeth J. DavisVanderbilt University/Ingram Cancer Center4 years of reported clinical research
Studies Sarcoma
Studies Tumors
16 reported clinical trials
21 drugs studied
David D. ChismThompson Cancer Survival Center4 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
14 reported clinical trials
42 drugs studied
Clinical Trials running at Vanderbilt-Ingram Cancer Center
Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Breast Cancer
Lung Cancer
Multiple Myeloma
Lymphoma
Leukemia
Pancreatic Cancer
Anal Cancer
Genetic-Guided Therapy
for Kidney Cancer
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or metastatic). The current Food and Drug Administration (FDA)-approved regimens for advanced kidney cancer fall into two categories. One treatment combination includes two immunotherapy drugs (nivolumab plus ipilimumab), which are delivered by separate intravenous infusions into a vein. The other combination is one immunotherapy drug (nivolumab infusion) plus an oral pill taken by mouth (cabozantinib). Nivolumab and ipilimumab are "immunotherapies" which release the brakes of the immune system, thus allowing the patient's own immune system to better kill cancer cells. Cabozantinib is a "targeted therapy" specifically designed to block certain biological mechanisms needed for growth of cancer cells. In kidney cancer, cabozantinib blocks a tumor's blood supply. The genetic (DNA) makeup of the tumor may affect how well it responds to therapy. Testing the makeup (genes) of the tumor, may help match a treatment (from one of the above two treatment options) to the specific cancer and increase the chance that the disease will respond to treatment. The purpose of this study is to learn if genetic testing of tumor tissue may help doctors select the optimal treatment regimen to which advanced kidney cancer is more likely to respond.
Recruiting3 awards Phase 214 criteria
Reduced-Intensity Chemoradiation
for Anal Cancer
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.
Recruiting3 awards Phase 25 criteria
Immunotherapy + Radiation
for Head and Neck Cancer
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Recruiting2 awards Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Vanderbilt-Ingram Cancer Center?
Vanderbilt-Ingram Cancer Center is a medical facility located in Nashville, Tennessee. This center is recognized for care of Cancer, Leukemia, Tumors, Lymphoma, Breast Cancer and other specialties. Vanderbilt-Ingram Cancer Center is involved with conducting 1,090 clinical trials across 833 conditions. There are 68 research doctors associated with this hospital, such as Scott Borinstein, M.D., Michael Gibson, Elizabeth J. Davis, and David D. Chism.
Where is Vanderbilt-Ingram Cancer Center located?
**Vanderbilt-Ingram Cancer Center**
- **Location:** 2220 Pierce Avenue, Nashville, TN.
- **Parking:** South Garage, 1504 24th Ave. S., Nashville, TN 37212.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Vanderbilt-Ingram Cancer Center, call 1-877-936-8422 or visit their [financial assistance page](http://www.vanderbilthealth.com/information/financial-assistance) for details on their policy and payment plan options. They provide a plain language summary of their financial assistance program. For insurance inquiries, visit the [Vanderbilt Health Insurance office](http://www.vanderbilt.edu/financialaid/faforms/vandyhealthwaiver.php).
What insurance does Vanderbilt-Ingram Cancer Center accept?
The Vanderbilt-Ingram Cancer Center accepts a variety of insurance plans, including but not limited to Aetna, Aetna Better Health (KY Medicaid), Ambetter of Tennessee (Commercial), BlueCross BlueShield, Cigna, and UnitedHealthcare. It's important to contact your insurance provider to confirm coverage for services at Vanderbilt facilities. Note: Vanderbilt Health is out of network for Humana's Medicare Advantage HMO and Humana Kentucky Medicaid - Health Horizons as of April 16, 2023.
What awards or recognition has Vanderbilt-Ingram Cancer Center received?
Vanderbilt-Ingram Cancer Center, located in Nashville, Tennessee, is recognized as a Comprehensive Cancer Center by the National Cancer Institute (NCI), the only one in Tennessee offering research and care for both adults and children with cancer. It is a member of the National Comprehensive Cancer Network (NCCN) and a Lead Academic Participating Site in the NCI's National Clinical Trials Network (NCTN). The center secures approximately $142 million annually in research support and holds two NCI Specialized Programs of Research Excellence (SPORE) grants for gastrointestinal (GI) and breast cancers.